Rubicon Genomics Launches ThruPlex Products For Sequencing Applications
ANN ARBOR -- Rubicon Genomics Inc. Wednesday announced the launch of the first product in its innovative ThruPlex family of sample preparation kits designed and optimized for next generation sequencing.
ThruPlex-FD kits use Rubicon's patented DNA repair and ligation methods to deliver significantly faster and more sensitive sequencing of plasma, formalin-fixed, ChIP and other fragmented DNA with substantially increased throughput.
ThruPLEX kits are also applicable to sample preparation for PCR and microarray testing.
"The accelerated adoption of NGS technology has created a demand for faster and more sensitive sample preparation," said James Koziarz, CEO of Rubicon. "Breaking with the traditional multi-step process requiring intermediate transfers and purifications, ThruPLEX uses more efficient enzymology to repair, ligate and amplify the DNA molecules in a single tube. Our patented three-step process enables high quality sequencing of clinical samples that were previously too small or degraded to be tested."
Henry Long, associate director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute, said: "Our experience with the ThruPLEX-FD library prep has been extremely positive. Both at Rubicon and in our hands it has proven able to generate high quality, diverse libraries from 10-times less input than other kits we have used. For us this technology truly enables the study of samples that simply weren't possible before adopting it."
ThruPlex-FD is a streamlined one-tube, three-step process without intermediate purifications, transfers, columns or gels. The reduced steps and material transfers decrease the likelihood of experimental variability, bias and contamination. DNA is sequencing-ready in two hours with as little as 15 minutes of hands-on time. A technician can prepare 192 ThruPlex samples a day -- a 15-fold increase in productivity compared to current methods.
ThruPlex-FD is designed and validated for use with samples as small as 50 picograms of human DNA and can be used in plasma, FFPE, cDNA, ChIP and population studies.
ThruPlexFD is currently available as 48-reaction, 12-index kits for sequencing on Illumina HiSeq, MiSeq and Genome Analyzer instruments. ThruPlex-FD kits are also being developed for additional formats and platforms.
For more information about ThruPlex-FD, visit www.rubicongenomics.com/products/ThruPlex-FD.
Separately, Rubicon announced that Kenneth Solomon has joined the company as director of sales and marketing. Solomon has extensive experience in marketing, sales and sales management for technologically advanced biomedical products, holding positions of increasing responsibility at Centocor Ortho Biotech, Pharmacia/Searle, Biomet, Boehringer Mannheim and others.
